New hope for rare kidney cancer: drug cocktail aims to prevent relapse after surgery
NCT ID NCT07488533
First seen Mar 25, 2026 · Last updated Jun 08, 2026 · Updated 13 times
Summary
This study tests whether two drugs, Serplulimab and Fruquintinib, can prevent a rare kidney cancer (non-clear cell renal cell carcinoma) from returning after surgery. About 40 adults at high risk of recurrence will receive both drugs for up to 12 months. The goal is to see how long they stay cancer-free and whether the treatment is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.